WestPark Capital Initiates Coverage On Veru with Buy Rating, Announces Price Target of $28
WestPark Capital analyst Ed Arce initiates coverage on Veru (NASDAQ:VERU) with a Buy rating and announces Price Target of $28.
Stocks · News reference
Veru Completes Patient Enrollment In Phase 2b PLATEAU Clinical Trial To Evaluate Effect Of Oral Enobosarm 3 Mg Versus To Treat Obesity
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the completion of
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — VERU INC. (VERU)
Filed: 2026-09-08 AccNo: 0001193125-26-384430 Size: 202 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Veru shares are trading higher after the company reported better-than-expected Q3 EPS results.
Veru Q3 EPS $(0.30) Beats $(0.32) Estimate
Veru (NASDAQ:VERU) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.32) by 6.25 percent. This is a 40 percent increase over losses of $(0.50) per share from the same period